BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda
March 24, 2017 at 09:14 AM EDT
* European Medicines Agency's CHMP recommends approval of Merck's keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical hodgkin lymphoma
